Literature DB >> 26768997

Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.

Hannah Cookson1, John McFadden1, Jonathan White1, Ian R White1.   

Abstract

Entities:  

Keywords:  brimonidine tartrate; contact allergy

Mesh：

Substances：

Year:  2015        PMID： 26768997     DOI： 10.1111/cod.12476

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN： 0105-1873            Impact factor:   6.600


× No keyword cloud information.
  4 in total

Review 1.  Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.

Authors:  Michael S Anderson; Anish Nadkarni; Leah A Cardwell; Hossein Alinia; Steven R Feldman
Journal:  Patient Prefer Adherence       Date:  2017-07-06       Impact factor: 2.711

Review 2.  Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition.

Authors:  Yu Ri Woo; Ji Hong Lim; Dae Ho Cho; Hyun Jeong Park
Journal:  Int J Mol Sci       Date:  2016-09-15       Impact factor: 5.923

3.  The Evaluation of Contact Sensitivity with Standard and Cosmetic Patch Test Series in Rosacea Patients.

Authors:  Hilal Kaya Erdogan; Isil Bulur; Zeynep Nurhan Saracoglu; Muzaffer Bilgin
Journal:  Ann Dermatol       Date:  2018-04-23       Impact factor: 1.444

Review 4.  Rosacea: Epidemiology, pathogenesis, and treatment.

Authors:  Barbara M Rainer; Sewon Kang; Anna L Chien
Journal:  Dermatoendocrinol       Date:  2017-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.